Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Roxadustat, a hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, was first introduced in Japan in 2019 and subsequently adopted in several countries for anemia management in chronic kidney disease (CKD) and hemodialysis (HD) patients. Although initially more expensive than erythropoiesis-stimulating agents (ESAs), HIF-PH inhibitors represent a novel therapeutic class with broader metabolic effects through activation of multiple hypoxia-responsive genes. This study investigated the long-term cost trajectory and dose trends of roxadustat compared with conventional EPO therapy in HD patients.
Seventy-two stable maintenance HD patients previously treated with EPO (9,000 U/week) were switched to roxadustat at 100 mg, three times per week. The dose was titrated to maintain hemoglobin (Hb) levels between 10–12 g/dL. Ferrokinetic parameters were monitored, and iron supplementation was adjusted as needed. The cost per week was estimated using average retail prices in Japan. Longitudinal changes in dose, cost, and clinical indices—including GNRI and CRP—were analyzed over 100 weeks.
The initial weekly dose of roxadustat averaged 261 mg, corresponding to approximately 4,000 JPY/week—significantly higher than EPO (≈ 2,600 JPY/week). The dose gradually declined over the first 50 weeks, followed by an accelerated reduction beyond 60 weeks. After 100 weeks, the average dose and cost decreased to 65% of the initial level. GNRI slightly declined (92 ± 12.4 → 87 ± 8.9), and CRP rose modestly (0.3 ± 0.14 → 0.8 ± 0.14 mg/dL), neither reaching statistical significance. No severe adverse events were reported.
Long-term treatment with roxadustat demonstrated progressive dose and cost reductions comparable to EPO over a 100-week period. These findings suggest sustained hematopoietic efficacy with potential cost-saving benefits in HD patients. Further studies are warranted to elucidate the underlying mechanisms contributing to long-term dose optimization beyond nutritional or inflammatory influences.
